Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SBRT and 177Lu-DOTATATE for Large Gastrointestinal Neuroendocrine Tumors
NCT07150546Phase 1Recruiting
- Sponsor
- Emory University
- Start
- Oct 2025
- Primary completion
- Sep 2026
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of lutetium Lu 177 dotatate in gastrointestinal neuroendocrine neoplasm (GI-NEN), sponsored by Emory University. Primary endpoint: Incidence of Acute Grade 3+ Non-Hematologic Adverse Events at 3 months. Started Oct 2025; status: recruiting.
02
Drugs
lutetium Lu 177 dotatate
03
Conditions
gastrointestinal neuroendocrine neoplasm (GI-NEN)
Beyond the preview
Go deeper on NCT07150546.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07150546.